Radiopharm Theranostics Future Growth
Future criteria checks 0/6
Radiopharm Theranostics is forecast to grow earnings and revenue by 10.9% and 50.2% per annum respectively while EPS is expected to decline by 9.1% per annum.
Key information
10.9%
Earnings growth rate
-9.1%
EPS growth rate
| Biotechs earnings growth | 15.3% |
| Revenue growth rate | 50.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 70 | -38 | -10 | -6 | 3 |
| 6/30/2026 | 22 | -35 | -42 | -39 | 3 |
| 6/30/2025 | N/A | -52 | -58 | -55 | 3 |
| 6/30/2024 | 2 | -48 | -23 | -23 | N/A |
| 3/31/2024 | 4 | -47 | -24 | -23 | N/A |
| 12/31/2023 | 6 | -47 | -24 | -23 | N/A |
| 9/30/2023 | 6 | -41 | -25 | -23 | N/A |
| 6/30/2023 | 6 | -35 | -25 | -23 | N/A |
| 3/31/2023 | 5 | -30 | -21 | -20 | N/A |
| 12/31/2022 | 4 | -26 | -18 | -17 | N/A |
| 9/30/2022 | 2 | -28 | -28 | -14 | N/A |
| 6/30/2022 | N/A | -30 | -38 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RAD is forecast to have no revenue next year.
High Growth Revenue: RAD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RAD's Return on Equity is forecast to be high in 3 years time